Revolution Medicines promotes Jack Anders to CFO effective Sept 1, 2022

Revolution Medicines, Inc.

Jack Anders, age 45, appointed CFO effective immediately; previously SVP Finance and Principal Financial and Accounting Officer.
Anders joined Revolution Medicines in August 2018; prior roles at Depomed (VP Finance), Elan Pharmaceuticals, Yahoo!, and Novellus Systems.
He began his career at PricewaterhouseCoopers and holds a B.A. in Economics from UCLA; formerly a CPA.
Anders will continue as Principal Financial and Accounting Officer; no departure of prior CFO announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jack Anders

Chief Financial Officer

RVMD · Revolution Medicines, Inc.

Effective: 2022-09-01
Filed: September 1, 2022, 7:59 PM ET

On September 1, 2022, the Board of Directors (the “Board”) of Revolution Medicines, Inc. (the “Company”) promoted Jack Anders, age 45, to serve as the Chief Financial Officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jack Anders changed role as Chief Financial Officer at Revolution Medicines, Inc..

Action: promoted
Role: Chief Financial Officer

Exact text from the filing

On September 1, 2022, the Board of Directors (the “Board”) of Revolution Medicines, Inc. (the “Company”) promoted Jack Anders, age 45, to serve as the Chief Financial Officer of the Company, effective immediately.

View on SEC.gov

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-236516

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.